Published in

Impact Journals, Aging, 8(1), p. 714-722, 2009

DOI: 10.18632/aging.100071

Links

Tools

Export citation

Search in Google Scholar

Human insulin/IGF-1 and familial longevity at middle age

Journal article published in 2009 by Maarten P. Rozing, Rudi G. J. Westendorp, Marijke Frölich, M. Fr{̈o}lich, Anton J. M. de Craen, Marian Beekman, Bastiaan T. Heijmans, Simon P. Mooijaart ORCID, Gerard-Jan Blauw, P. Eline Slagboom ORCID, P. Eline Slagboom, Diana van Heemst, on behalf of the Leiden Longevity Study (LLS) Group, {Leiden Longevity Study (LLS) Group}
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Recently, we have shown that compared to controls, long-lived familial nonagenarians (mean age: 93.4 years) from the Leiden Longevity Study displayed a lower mortality rate, and their middle-aged offspring displayed a lower prevalence of cardio-metabolic diseases, including diabetes mellitus. The evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has been implicated in longevity in model organisms, but its relevance for human longevity has generated much controversy. Here, we show that compared to their partners, the offspring of familial nonagenarians displayed similar non-fasted serum levels of IGF-1, IGFBP3 and insulin but lower non-fasted serum levels of glucose, indicating that familial longevity is associated with differences in insulin sensitivity.